Engineering immunotherapeutic probiotics to mitigate irAE

  • Danino, Tal (PI)
  • Arpaia, Nicholas (CoPI)

Projet

Détails sur le projet

Description

PROJECT NARRATIVE Cancer immunotherapies have demonstrated significant clinical success for subgroups of patients with varying malignancies. However, due in part to their systemic administration, therapeutic limitations include immune- related adverse effects and diminished efficacy due to poor tumor penetration. This proposal seeks to engineer immunotherapeutic probiotic bacteria that target primary cancers and associated metastases and locally deliver immunotherapy and adjuvants to stimulate systemic antitumor immunity with minimal side effects.
StatutTerminé
Date de début/de fin réelle1/21/2012/31/22

Financement

  • National Cancer Institute: 1 152 227,00 $ US
  • National Cancer Institute: 596 099,00 $ US

Keywords

  • Inmunología
  • Oncología

Empreinte numérique

Explorer les sujets de recherche abordés dans ce projet. Ces étiquettes sont créées en fonction des prix/bourses sous-jacents. Ensemble, ils forment une empreinte numérique unique.